Etoposide

Indications
 Intravenous
Testicular cancer
Adult: For combination therapy: 50-100 mg/m2 BSA/day from days 1-5, or 100 mg/m2 on days 1, 3 and 5. May repeat course at 3-4 wkly intervals after recovery from any toxicity. Inj must be diluted with 5% dextrose or normal saline to give a final concentration of 0.2-0.4 mg/ml and injected over 30-60 minutes.
CrCl (ml/min)Dosage Recommendation
15-5075% of the recommended dose.

Intravenous
Small cell lung cancer
Adult: 35 mg/m2 BSA/day for 4 days to 50 mg/m2 BSA/day for 5 days. May repeat course at 3-4 wkly intervals after recovery from any toxicity. Inj must be diluted with 5% dextrose or normal saline to give a final concentration of 0.2-0.4 mg/ml and injected over 30-60 minutes. When given via oral capsules: the recommended dose is twice the IV dose rounded to the nearest 50 mg.
Contraindications
 Hypersensitivity, pregnancy, lactation.
Warnings / Precautions
 Skin reactions may occur with accidental exposure; renal or hepatic disease. Periodic CBCs should be done before, during and after therapy. Increased risk of etoposide-toxicity in patients with low serum albumin. Acrylic material has been shown to crack and leak when used with undiluted etoposide inj.
Adverse Reactions
 Nausea, vomiting, anorexia, diarrhoea, stomatitis; reversible alopoecia; rarely, disturbances of liver dysfunction, peripheral neuropathy, CNS effects, anaphylactoid reactions; hypotension with IV injection. Local irritation and thrombophloebitis at the site of inj.
Potentially Fatal: Severe myelosuppression, characterised by leucopaenia and thrombocytopaenia. Cardiotoxicity. Anaphylaxis.
Drug Interactions
 Synergism with other cytotoxic drugs. Caution when admin with drugs that inhibit phosphatase activity. Cyclosporin A may reduce the clearance of etoposide.
See Below for More etoposide Drug Interactions
Mechanism of Actions
 Etoposide is a derivative of podophyllotoxin that inhibits DNA synthesis resulting in the arrest of the cell cycle. At low doses, it inhibits cells from entering cell cycle and at high doses, cells entering mitosis are lysed.
Absorption: Oral admin: 50% absorbed from the GI tract; plasma concentrations peak after 1 hr.
Distribution: Rapid distribution but poor penetration of the blood-brain barrier. Protein-binding: 94%.
Metabolism: Metabolised by CYP3A4.
Excretion: Terminal half-life: 4-11 hr. Excreted in urine and faeces.
Administration
 Should be taken on an empty stomach. (Take on an empty stomach.)
Storage Conditions
 Intravenous: Refrigerate at 2-8°C. Do not freeze. Conc for inj: Store at 15-30°C.
ATC Classification
 L01CB01 - etoposide ; Belongs to the class of plant alkaloids and other natural products, podophyllotoxin derivatives. Used in the treatment of cancer.
Storage
 Intravenous: Refrigerate at 2-8°C. Do not freeze. Conc for inj: Store at 15-30°C.
Available As
  • Etoposide 100 mg
  • Etoposide 20 mg
  • Etoposide 25 mg
  • Etoposide 50 mg

    • Subscribe for latest updates

    Subscribe to our e-mail newsletter to receive updates.

    No comments yet.

    Post Review about Etoposide


    Etoposide Containing Brands

    We are Developing Our database, More results coming soon.

    Etoposide is used in following diseases

    We are Developing Our database, More results coming soon.

    Drug - Drug Interactions of Etoposide

    We are Developing Our database, More results coming soon.